Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHARMACOKINETIC (PK) DRUG-DRUG INTERACTION BETWEEN SAMATASVIR (IDX719), A PAN-GENOTYPIC NS5A INHIBITOR, AND SIMEPREVIR IN HEALTHY VOLUNTEERS AND HCV-INFECTED SUBJECTS

Next Previous
Search
Trial Profile

PHARMACOKINETIC (PK) DRUG-DRUG INTERACTION BETWEEN SAMATASVIR (IDX719), A PAN-GENOTYPIC NS5A INHIBITOR, AND SIMEPREVIR IN HEALTHY VOLUNTEERS AND HCV-INFECTED SUBJECTS

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Samatasvir (Primary) ; Simeprevir (Primary)
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Sponsors Idenix Pharmaceuticals; Janssen

Most Recent Events

  • 15 May 2014 New trial record
  • 09 Apr 2014 Results presented at the 49th Annual Meeting of the European Association for the Study of the Liver.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top